Loading clinical trials...
Loading clinical trials...
Phase Ib Study of Recombinant Anti-PD-L1 Monoclonal Antibody Injection (ZKAB001) Combined With Carboplatin and Etoposide in the Treatment of Extensive Small Cell Lung Cancer
Conditions
Interventions
recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide
Locations
1
China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Start Date
March 8, 2020
Primary Completion Date
October 30, 2022
Completion Date
October 30, 2022
Last Updated
May 11, 2022
NCT07037758
NCT05142696
NCT05468489
NCT07547332
NCT06323265
NCT05055999
Lead Sponsor
Lee's Pharmaceutical Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions